Research programme: cancer metabolism modulators - Dynamix

Drug Profile

Research programme: cancer metabolism modulators - Dynamix

Alternative Names: DNX-03000; DNX-03024; DNX-06000; DNX-3000; DNX-6000; PKM2 activators - Dynamix

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Dynamix Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action Glycolysis modulators; Pyruvate kinase modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • Available For Licensing Yes

Highest Development Phases

  • No development reported Solid tumours

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Solid-tumours in Israel (PO)
  • 15 Jun 2011 Research programme: cancer metabolism enzyme modulators - Dynamix is available for licensing as of 15 Jun 2011.
  • 05 Apr 2011 Preclinical trials in Solid tumours in Israel (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top